Stacy Ann Stratemann Killen

Dr. Stacy Ann Stratemann Killen


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
AKAlexander M Kaizer
Alexander M Kaizer
AWAnnika Winbo
Annika Winbo
SCSally-Ann B Clur
Sally-Ann B Clur
SESusan P Etheridge
Susan P Etheridge
MAMichael J Ackerman
Michael J Ackerman
BCBettina Cuneo
Bettina Cuneo
In long QT syndrome (LQTS), primary prevention improves outcome; thus, early identification is key. The most common LQTS phenotype is a foetal heart rate (FHR) < 3rd percentile for gestational age (GA) but the effects of cohort, genotype, variant, and maternal β-blocker therapy on FHR are unknown. We assessed the influence of these factors on FHR in pregnancies with familial LQTS and developed a FHR/GA threshold for LQTS. In an international cohort of pregnancies in which one parent had LQTS, LQTS genotype, familial variant, and maternal β-blocker effects on FHR were assessed. We developed a testing algorithm for LQTS using FHR and GA as continuous predictors. Data included 1966 FHRs at 7–42 weeks’ GA from 267 pregnancies/164 LQTS families [220 LQTS type 1 (LQT1), 35 LQTS type 2 (LQT2), and 12 LQTS type 3 (LQT3)]. The FHRs were significantly lower in LQT1 and LQT2 but not LQT3 or LQTS negative. The LQT1 variants with non-nonsense and severe function loss (current density or β-adrenergic response) had lower FHR. Maternal β-blockers potentiated bradycardia in LQT1 and LQT2 but did not affect FHR in LQTS negative. A FHR/GA threshold predicted LQT1 and LQT2 with 74.9% accuracy, 71% sensitivity, and 81% specificity. Genotype, LQT1 variant, and maternal β-blocker therapy affect FHR. A predictive threshold of FHR/GA significantly improves the accuracy, sensitivity, and specificity for LQT1 and LQT2, above the infant’s a priori 50% probability. We speculate this model may be useful in screening for LQTS in perinatal subjects without a known LQTS family history. Summary of findings from the manuscript.

SKStacy Ann Stratemann Killen
Stacy Ann Stratemann Killen
JSJanette F Strasburger
Janette F Strasburger
Diagnosis and management of fetal arrhythmias have changed over the past 40–50 years since propranolol was first used to treat fetal tachycardia in 1975 and when first attempts were made at in utero pacing for complete heart block in 1986. Ongoing clinical trials, including the FAST therapy trial for fetal tachycardia and the STOP-BLOQ trial for anti-Ro-mediated fetal heart block, are working to improve diagnosis and management of fetal arrhythmias for both mother and fetus. We are also learning more about how “silent arrhythmias”, like long QT syndrome and other inherited channelopathies, may be identified by recognizing “subtle” abnormalities in fetal heart rate, and while echocardiography yet remains the primary tool for diagnosing fetal arrhythmias, research efforts continue to advance the clinical envelope for fetal electrocardiography and fetal magnetocardiography. Pharmacologic management of fetal arrhythmias remains one of the most successful achievements of fetal intervention. Patience, vigilance, and multidisciplinary collaboration are key to successful diagnosis and treatment.

1 September 2022 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
SKSandra D. Kikano
Sandra D. Kikano
SKStacy Ann Stratemann Killen
Stacy Ann Stratemann Killen

30 October 2025 in Heart Rhythm
Verified
Journal Article
Open access
SKStacy Ann Stratemann Killen
Stacy Ann Stratemann Killen

28 December 2023 in Pediatric Cardiology
Verified
Journal Article
Closed access
PDF file
SKSandra Kikano
Sandra Kikano
SFSarah Fuchs
Sarah Fuchs
AVAndres Contreras Vega
Andres Contreras Vega
Ann Kavanaugh-McHughAnn Kavanaugh-McHugh
Ann Kavanaugh-McHugh
DBDavid Bichell
David Bichell
SKStacy Ann Stratemann Killen
Stacy Ann Stratemann Killen

Ann Kavanaugh-McHughAnn Kavanaugh-McHugh
Ann Kavanaugh-McHugh
LZLisa Zuckerwise
Lisa Zuckerwise
SKStacy Ann Stratemann Killen
Stacy Ann Stratemann Killen
EMEmily A. Morris
Emily A. Morris
RSRachel T. Sullivan
Rachel T. Sullivan
LFLindsay Freud
Lindsay Freud
Collaborative multicenter research has significantly increased our understanding of fetal Ebstein anomaly, delineating risk factors for adverse outcomes as well as predictors of postnatal management. These data are incorporated into prenatal care and therapeutic strategies and inform family counseling and delivery planning to optimize care. This report details the translation of findings from multicenter studies into multidisciplinary prenatal care for a fetus with Ebstein anomaly, supraventricular tachycardia, and a circular shunt, including transplacental therapy to control arrhythmias and achieve ductal constriction, informed and coordinated delivery room management, and planned univentricular surgical palliation.